[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352873-105":59,"doc-detail-352873-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","thin-and-in-situ-melanoma-an-update-for-the-dermatologist","Thin and in situ melanoma: an update for the dermatologist","","Thin melanoma (TM, ≤ 1.0 mm Breslow thickness) and melanoma in situ (MIS) represent most melanoma diagnoses worldwide and drive melanoma-related deaths despite early-stage appearance. MIS and TM also offer a window to improve outcomes through timely detection, accurate risk stratification, and durable follow-up to identify metastasis and new skin neoplasms. The review synthesizes epidemiology, risk factors, prognostic indicators, genetic background, and evidence-based clinical management, emphasizing long-term surveillance and multidisciplinary care.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/thin-and-in-situ-melanoma-an-update-for-the-dermatologist/352873/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/thin-and-in-situ-melanoma-an-update-for-the-dermatologist/352873.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are Thin Melanoma (TM) and Melanoma In Situ (MIS)?","Question",{"text":112,"@type":113},"TM is defined as thin melanoma with Breslow thickness ≤ 1.0 mm, and MIS refers to melanoma in situ. Together they represent the majority of melanoma diagnoses worldwide.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are MIS and TM clinically important despite favorable prognosis?",{"text":117,"@type":113},"They account for most melanomas and can still lead to melanoma-related deaths. They also signal risk for subsequent primary melanomas and other cutaneous neoplasms, making long-term surveillance necessary.",{"name":119,"@type":110,"acceptedAnswer":120},"How is prognosis for MIS and TM primarily assessed?",{"text":121,"@type":113},"Prognosis is primarily determined by Breslow depth and ulceration. Additional factors such as mitotic rate, anatomic site, and age refine risk assessment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352873,1790151279,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","REVIEW  \nThin and in situ melanoma: an update for the dermatologist􀀂  \nJoão Renato Vianna Gontijo  a,b,∗ , Flávia Vasques Bittencourt a, Jacob H . Nelson c, Lucas Campos Garcia a,b, Sancy A . Leachman c,d  \na Department of Internal Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil b Service of Dermatology, Rede Mater Dei de Saúde, Belo Horizonte, MG, Brazil  \nc Department of Dermatology, School of Medicine, Oregon Health and Science University, Portland, OR, United States of America d Department of Dermatology, School of Medicine, University of Utah, Salt Lake City, UT, United States of America  \nReceived 24 November 2025; accepted 1 January 2026  \nKEYWORDS  \nMelanoma; Neoplasm metastasis; Prognosis; Recurrence  \nAbstract  \nBackground: Thin melanoma (TM, ≤ 1.0 mm Breslow thickness) and Melanoma In Situ (MIS) constitute the majority of melanoma diagnoses worldwide and are responsible for melanomarelated deaths in these early-stage tumors. Despite their favorable prognosis, MIS and TM represent an opportunity for improving patient outcomes through early detection, accurate risk stratification, and long-term surveillance for metastasis and new skin neoplasms. Objective: Provide an update of current evidence regarding epidemiology, risk factors, prognostic indicators, genetic background, and clinical management of MIS and TM.  \nMethods: A comprehensive review of the literature and international guidelines was conducted, integrating epidemiologic data, clinical prognostic parameters, and molecular insights relevant to MIS and TM.  \nResults: MIS and TM account for over 80% of all melanomas, with increasing incidence and relatively stable mortality rates. Prognosis is primarily determined by Breslow depth and ulceration, while factors such as mitotic rate, anatomic site, and age further refine risk assessment. Genetic alterations contribute to tumorigenesis but are not yet integrated into routine management. Long-term dermatological surveillance is needed, as new neoplasms, recurrence, and metastasis can develop during follow-up.  \nConclusions: MIS and TM are increasingly diagnosed, and dermatologists need to be a part of early detection, multidisciplinary management, and lifelong surveillance, which remain the cornerstone of reducing melanoma-related mortality.  \nStudy limitations: The substantial heterogeneity among the included studies limits direct comparison and quantitative synthesis of the available data.  \n© 2026 Sociedade Brasileira de Dermatologia. Published by Elsevier Espaa, S.L.U. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) ).  \n􀀂 Study conducted at the Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.  \n∗ Corresponding author.  \nE-mail: [joaorenatogontijo@gmail.com](joaorenatogontijo@gmail.com) (J.R. Gontijo).  \n[https://doi.org/10.1016/j.abd.2026.501349](https://doi.org/10.1016/j.abd.2026.501349)  \n0365-0596/© 2026 Sociedade Brasileira de Dermatologia. Published by Elsevier Espaa, S.L.U. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nIntroduction  \nIn recent years, advances in the genetic characterization of melanomas, early diagnosis, and new treatments have changed the perspective and knowledge of this tumor. Even in the absence of a defined model of melanoma evolution, the clinical and epidemiological importance of Melanoma In Situ (MIS) and Thin Melanoma (TM) (Breslow thickness ≤ 1.0 mm), which comprises the vast majority of cases, is well established.  \nIncreased use of dermoscopy, translation of novel technologies into clinical practice, improved melanoma awareness in clinical practice and public health campaigns all contribute to earlier diagnosis of skin tumors, leading to an increasing number of patients with MIS and TM being ","cbCaisiARx9QBRUT","https://ap.wps.com/l/cbCaisiARx9QBRUT","pdf",2344516,13,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusions\n## Study limitations\n# Introduction\n# Epidemiology","[{\"question\":\"What are Thin Melanoma (TM) and Melanoma In Situ (MIS)?\",\"answer\":\"TM is defined as thin melanoma with Breslow thickness ≤ 1.0 mm, and MIS refers to melanoma in situ. Together they represent the majority of melanoma diagnoses worldwide.\"},{\"question\":\"Why are MIS and TM clinically important despite favorable prognosis?\",\"answer\":\"They account for most melanomas and can still lead to melanoma-related deaths. They also signal risk for subsequent primary melanomas and other cutaneous neoplasms, making long-term surveillance necessary.\"},{\"question\":\"How is prognosis for MIS and TM primarily assessed?\",\"answer\":\"Prognosis is primarily determined by Breslow depth and ulceration. Additional factors such as mitotic rate, anatomic site, and age refine risk assessment.\"}]","Thin and in situ melanoma: an update for the dermatologist | PDF",1790101823,33]